Biotech Co. Beats Investor Suit Over Antifungal Drug Recall

Biotechnology company Scynexis Inc. has won dismissal, for now, of a proposed investor class action alleging that it triggered a 34% share decline by knowingly misleading investors about manufacturing compliance issues...

Already a subscriber? Click here to view full article